Wedbush Forecasts Biogen's Q3 Earnings (NASDAQ:BIIB)

Key Points

• Wedbush has lowered its Q3 2025 EPS estimate for Biogen to $3.76, down from $3.81, while maintaining a "Neutral" rating and a target price of $121.00.
• Biogen recently reported Q2 earnings of $5.47 EPS, exceeding expectations by $1.54, with revenues reaching $2.65 billion, surpassing analyst estimates of $2.32 billion.
• A majority of analysts currently rate Biogen stock as "Hold" with an average target price of $185.63, reflecting cautious sentiment among financial experts.

Biogen Inc. (NASDAQ:BIIB - Free Report) - Stock analysts at Wedbush dropped their Q3 2025 EPS estimates for shares of Biogen in a note issued to investors on Thursday, July 31st. Wedbush analyst L. Chico now anticipates that the biotechnology company will post earnings per share of $3.76 for the quarter, down from their prior estimate of $3.81. Wedbush currently has a "Neutral" rating and a $121.00 target price on the stock. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. Wedbush also issued estimates for Biogen's FY2025 earnings at $15.96 EPS, Q1 2026 earnings at $3.75 EPS and Q3 2026 earnings at $3.72 EPS.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $5.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.93 by $1.54. Biogen had a net margin of 15.31% and a return on equity of 13.85%. The company had revenue of $2.65 billion for the quarter, compared to analyst estimates of $2.32 billion. During the same period last year, the business posted $5.28 EPS. The business's quarterly revenue was up 7.3% on a year-over-year basis.

Other equities analysts also recently issued reports about the stock. Morgan Stanley cut their price target on shares of Biogen from $146.00 to $144.00 and set an "equal weight" rating for the company in a report on Friday. Canaccord Genuity Group cut their price target on shares of Biogen from $265.00 to $220.00 and set a "buy" rating for the company in a report on Friday, May 2nd. HSBC downgraded shares of Biogen from a "buy" rating to a "hold" rating and set a $118.00 target price for the company. in a research note on Monday, April 28th. Mizuho dropped their target price on shares of Biogen from $207.00 to $169.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Finally, Oppenheimer set a $205.00 target price on shares of Biogen in a research note on Friday, May 2nd. Twenty-one equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, Biogen presently has an average rating of "Hold" and an average target price of $185.63.

Biogen Price Performance

Shares of Biogen stock opened at $131.95 on Monday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.79 and a current ratio of 2.50. The firm's 50-day simple moving average is $129.84 and its 200-day simple moving average is $131.69. Biogen has a twelve month low of $110.04 and a twelve month high of $213.50. The firm has a market cap of $19.35 billion, a P/E ratio of 12.61, a price-to-earnings-growth ratio of 1.78 and a beta of 0.13.

Hedge Funds Weigh In On Biogen

A number of hedge funds have recently bought and sold shares of BIIB. Opal Wealth Advisors LLC bought a new position in Biogen during the first quarter worth about $26,000. Vision Financial Markets LLC bought a new position in Biogen during the first quarter worth about $27,000. Greykasell Wealth Strategies Inc. bought a new position in Biogen during the first quarter worth about $27,000. Colonial Trust Co SC grew its stake in Biogen by 9,300.0% during the fourth quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company's stock worth $29,000 after buying an additional 186 shares in the last quarter. Finally, Zions Bancorporation National Association UT acquired a new stake in Biogen during the first quarter worth about $29,000. 87.93% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, insider Rachid Izzar sold 2,223 shares of the stock in a transaction dated Tuesday, July 8th. The shares were sold at an average price of $135.00, for a total value of $300,105.00. Following the transaction, the insider directly owned 6,330 shares of the company's stock, valued at $854,550. This represents a 25.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.18% of the stock is currently owned by corporate insiders.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.